London – April 7, 2021 – QualityAI, the world’s leading AI-powered, engineering-driven software testing and quality assurance company, announced today the acquisition of Israel-based Comply, a quality assurance specialist in Pharma and Digital Health.
QualityAI operates in a market that is growing at a 10% annual rate driven by the increasing needs of a $32 billion global outsourced market. The deal is expected to close this week. This is QualityAI’s second high-profile acquisition in 2021 and reinforces the company’s stronghold in the €8 billion medical technology testing market.
The deal will add 83 of Comply’s employees into the QualityAI team and will add Teva, Merck, Johnson & Johnson, GE Medical and AbbVie to QualityAI’s list of high-profile clients. Following the acquisition, Teva will become one of QualityAI’s leading pharmaceutical accounts globally.
As a strategic partner, QualityAI helps brands move beyond functional testing to adopt new innovations such as automation, AI and crowd sourced UX testing. It leverages its domain expertise across industries, including insurance and financial services, media and entertainment, retail, consumer goods, technology, gaming, telecom, aerospace, among others.
Founded in 2005, Comply provides quality assurance services for web, cloud and mobile applications related to digital health products. In particular, the company has focused on the validation of computerized systems, including enterprise IT and laboratory systems, as well as validation of IT infrastructure, such as information security and disaster recovery plans.
“We’ve had our eyes on Comply for a while due to its reputation as a leader in providing software testing services to the growing pharma tech market,” said Norm Merritt, QualityAI CEO. “That’s why we are excited to bring them into the QualityAI family. We see a lot of potential in the pharma industry, and by integrating Comply’s expertise we can expand QualityAI’s footprint in this hot-growth area,” he added.
“QualityAI is a global leader in testing, which is why it’s the perfect partner to help us take our testing services worldwide,” said Gai Anbar, Founder and CEO at Comply. “We have been impressed with QualityAI’s position as the go-to provider for software testing. By joining forces, we can capitalize on our own expertise in providing the highest quality assurance for health and pharma businesses,” he added.
About QualityAI:
Founded in 1997, QualityAI offers a wide range of AI-powered quality engineering and testing solutions, designed to mitigate the business risk associated with software releases. QualityAI achieves this by deploying engagement models tailored to the precise testing needs of technology platforms in the technology, financial services, retail, telecom, healthcare, insurance, aerospace, media and utilities industries. It has operations in Israel (where it was founded), the US, UK, and Romania, and serves over 250 blue-chip customers worldwide. QualityAI is majority-owned by international private equity group Bridgepoint, which acquired the company in October 2019 via its €5.7 billion flagship fund BE VI. To learn more about QualityAI, visit www.quality-ai.com.